Guillermo Torre-Amione

List of Publications by Year
in descending order

174 papers	13,010 citations	30070 54 h-index	24258 110 g-index
179 all docs	179 docs citations	179 times ranked	11928 citing authors

#	Article	IF	Citations
1	Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology, 1996, 27, 1201-1206.	2.8	1,098
2	Tumor Necrosis Factor-Î± and Tumor Necrosis Factor Receptors in the Failing Human Heart. Circulation, 1996, 93, 704-711.	1.6	833
3	Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy. Circulation, 2001, 103, 2254-2259.	1.6	515
4	Altered Titin Expression, Myocardial Stiffness, and Left Ventricular Function in Patients With Dilated Cardiomyopathy. Circulation, 2004, 110, 155-162.	1.6	436
5	Left Atrial Function in Diastolic Heart Failure. Circulation: Cardiovascular Imaging, 2009, 2, 10-15.	2.6	385
6	Cardiac Improvement During Mechanical Circulatory Support. Circulation, 2007, 115, 2497-2505.	1.6	376
7	Results of Targeted Antiâ€“Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure. Circulation, 2001, 103, 1044-1047.	1.6	358
8	Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. European Heart Journal, 2007, 29, 1283-1289.	2.2	354
9	Global Diastolic Strain Rate for the Assessment of Left Ventricular Relaxation and Filling Pressures. Circulation, 2007, 115, 1376-1383.	1.6	339
10	Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2007, 298, 2009.	7.4	330
11	Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support. Circulation, 2009, 119, 1263-1271.	1.6	292
12	Expression and Functional Significance of Tumor Necrosis Factor Receptors in Human Myocardium. Circulation, 1995, 92, 1487-1493.	1.6	284
13	Effects of Intracoronary CD34 ⁺ Stem Cell Transplantation in Nonischemic Dilated Cardiomyopathy Patients. Circulation Research, 2013, 112, 165-173.	4.5	256
14	Decreased Expression of Tumor Necrosis Factor-Î± in Failing Human Myocardium After Mechanical Circulatory Support. Circulation, 1999, 100, 1189-1193.	1.6	248
15	Immune Activation in Chronic Heart Failure. American Journal of Cardiology, 2005, 95, 3-8.	1.6	230
16	Estimation of left and right ventricular filling pressures after heart transplantation by tissue Doppler imaging. American Journal of Cardiology, 1998, 82, 352-357.	1.6	196
17	Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. Journal of Heart and Lung Transplantation, 2001, 20, 457-464.	0.6	187
18	Management of Myocarditis-Related Cardiomyopathy in Adults. Circulation Research, 2019, 124, 1568-1583.	4.5	179

#	Article	IF	Citations
19	Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet, The, 2002, 359, 936-941.	13.7	175
20	Differential Expression of Heat Shock Proteins in Normal and Failing Human Hearts. Journal of Molecular and Cellular Cardiology, 1998, 30, 811-818.	1.9	170
21	Comparison of Transendocardial and Intracoronary CD34 ⁺ Cell Transplantation in Patients With Nonischemic Dilated Cardiomyopathy. Circulation, 2013, 128, S42-9.	1.6	169
22	Left Ventricular Untwisting Rate by Speckle Tracking Echocardiography. Circulation, 2007, 116, 2580-2586.	1.6	164
23	Systolic and Diastolic Dyssynchrony in Patients With Diastolic Heart Failure and the Effect of Medical Therapy. Journal of the American College of Cardiology, 2007, 49, 88-96.	2.8	163
24	Comparative Tolerability of the HMG-CoA Reductase Inhibitors. Drug Safety, 2000, 23, 197-213.	3.2	160
25	Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet, The, 2008, 371, 228-236.	13.7	159
26	Percutaneous Placement of an Intra-Aortic Balloon Pump in the Left Axillary/Subclavian Position Provides Safe, Ambulatory Long-Term Support as Bridge to Heart Transplantation. JACC: Heart Failure, 2013, 1, 382-388.	4.1	135
27	Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clinical Microbiology and Infection, 2021, 27, 813-816.	6.0	122
28	Cellular and Hemodynamics Responses of Failing Myocardium to Continuous Flow Mechanical Circulatory Support Using the DeBakey-Noon Left Ventricular Assist Device: a Comparative Analysis With Pulsatile-Type Devices. Journal of Heart and Lung Transplantation, 2005, 24, 566-575.	0.6	115
29	Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. Journal of the American College of Cardiology, 2003, 42, 140-147.	2.8	113
30	Dobutamine stress echocardiography predicts myocardial improvement in patients supported by left ventricular assist devices (LVADs): hemodynamic and histologic evidence of improvement before LVAD explantation. Journal of Heart and Lung Transplantation, 2003, 22, 137-146.	0.6	112
31	Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure. Circulation, 2001, 103, 973-980.	1.6	108
32	Cytokines and acute heart failure. Critical Care Medicine, 2008, 36, S9-S16.	0.9	98
33	Increased right-to-left ventricle diameter ratio is a strong predictor of right ventricular failure after left ventricular assist device. Journal of Heart and Lung Transplantation, 2013, 32, 792-799.	0.6	98
34	Effects of Intracoronary Stem Cell Transplantation in Patients With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2011, 17, 272-281.	1.7	93
35	Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. Journal of the American College of Cardiology, 2004, 43, 811-817.	2.8	91
36	Myocardial Recovery in Peripartum Cardiomyopathy: Prospective Comparison With Recent Onset Cardiomyopathy in Men and Nonperipartum Women. Journal of Cardiac Failure, 2012, 18, 28-33.	1.7	91

#	Article	IF	Citations
37	Impact of Left Venticular Assist Device (LVAD)-mediated Humoral Sensitization on Post-transplant Outcomes. Journal of Heart and Lung Transplantation, 2005, 24, 2054-2059.	0.6	85
38	Persistent Blood Stream Infection in Patients Supported With a Continuous-Flow Left Ventricular Assist Device Is Associated With an Increased Risk of Cerebrovascular Accidents. Journal of Cardiac Failure, 2015, 21, 119-125.	1.7	85
39	An overview of tumor necrosis factor Î± and the failing human heart. Current Opinion in Cardiology, 1999, 14, 206.	1.8	77
40	Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. Journal of Heart and Lung Transplantation, 2010, 29, 195-200.	0.6	76
41	Mechanical Unloading Promotes Myocardial Energy Recovery in Human Heart Failure. Circulation: Cardiovascular Genetics, 2014, 7, 266-276.	5.1	76
42	Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidatesâ€”2006. Journal of Heart and Lung Transplantation, 2006, 25, 1043-1056.	0.6	70
43	Decreased Expression of Tumor Necrosis Factor-Î± and Regression of Hypertrophy After Nonsurgical Septal Reduction Therapy for Patients With Hypertrophic Obstructive Cardiomyopathy. Circulation, 2001, 103, 1844-1850.	1.6	68
44	Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal, 2005, 150, 46-53.	2.7	67
45	Full Expression of Cardiomyopathy Is Partly Dependent on Bâ€Cells: AÂPathway That Involves Cytokine Activation, Immunoglobulin Deposition, and Activation of Apoptosis. Journal of the American Heart Association, 2016, 5, .	3.7	67
46	Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. Journal of Cardiac Failure, 2015, 21, 179-188.	1.7	65
47	Echocardiographic Evaluation of Hemodynamics in Patients With Systolic Heart Failure Supported by a Continuous-Flow LVAD. Journal of the American College of Cardiology, 2014, 64, 1231-1241.	2.8	63
48	Tumor Necrosis Factor-Î±. Chest, 1999, 115, 1170-1174.	0.8	61
49	Left Ventricular Assist Device Support and Myocardial Recovery in Recent Onset Cardiomyopathy. Journal of Cardiac Failure, 2012, 18, 755-761.	1.7	61
50	New Therapeutics for Chronic Heart Failure. Annual Review of Medicine, 2002, 53, 59-74.	12.2	60
51	Impaired oxidative metabolism and calcium mishandling underlie cardiac dysfunction in a rat model of post-acute isoproterenol-induced cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H467-H477.	3.2	60
52	The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. American Journal of Surgery, 2000, 180, 498-502.	1.8	56
53	Early Worsening Heart Failure in Patients Admitted for Acute Heart Failure: Time Course, Hemodynamic Predictors, and Outcome. Journal of Cardiac Failure, 2009, 15, 639-644.	1.7	56
54	Cardiac Hypertrophy After Transplantation Is Associated With Persistent Expression of Tumor Necrosis Factor-Î±. Circulation, 2001, 104, 676-681.	1.6	55

#	Article	IF	Citations
55	The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor) Tj ETQq1 1 0.784314 rgBT /Over	7.1	55
56	Tumor necrosis factor-Î± and the failing human heart-TNFÎ± and heart failure. Clinical Cardiology, 1995, 18, IV20-IV27.	1.8	53
57	Effects of a novel immune modulation therapy in patients with advanced chronic heart failure. Journal of the American College of Cardiology, 2004, 44, 1181-1186.	2.8	53
58	Relationship of right- and left-sided filling pressures in patients with advanced heart failure: A 14-year multi-institutional analysis. Journal of Heart and Lung Transplantation, 2012, 31, 67-72.	0.6	52
59	Percutaneous Left Axillary Artery Placement of Intra-Aortic Balloon Pump in Advanced HeartÂFailure Patients. JACC: Heart Failure, 2020, 8, 313-323.	4.1	52
60	Evidence of improved right ventricular structure after LVAD support in patients with end-stage cardiomyopathy. Journal of Heart and Lung Transplantation, 2004, 23, 28-35.	0.6	51
61	Decorin-mediated Transforming Growth Factor-Î² Inhibition Ameliorates Adverse Cardiac Remodeling. Journal of Heart and Lung Transplantation, 2007, 26, 34-40.	0.6	51
62	The Role of Multimodality Cardiac Imaging in the Transplanted Heart. JACC: Cardiovascular Imaging, 2009, 2, 1126-1140.	5.3	50
63	Freshly isolated mitochondria from failing human hearts exhibit preserved respiratory function. Journal of Molecular and Cellular Cardiology, 2014, 68, 98-105.	1.9	49
64	Atrial arrhythmias after lung transplant: Underlying mechanisms, risk factors, and prognosis. Journal of Heart and Lung Transplantation, 2014, 33, 734-740.	0.6	49
65	Silica nanoparticles induce cardiotoxicity interfering with energetic status and Ca²⁺ handling in adult rat cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H645-H661.	3.2	49
66	Long-term Outcomes of Cardiac Transplantation for Peri-partum Cardiomyopathy: A Multiinstitutional Analysis. Journal of Heart and Lung Transplantation, 2007, 26, 1097-1104.	0.6	47
67	Mitochondrial Hyperacetylation in the Failing Hearts of Obese Patients Mediated Partly by a Reduction in SIRT3: The Involvement of the Mitochondrial Permeability Transition Pore. Cellular Physiology and Biochemistry, 2019, 53, 465-479.	1.6	46
68	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. American Journal of Cardiology, 2005, 95, 367-372.	1.6	43
69	Effects of a novel immune modulation therapy in patients with advanced chronic heart failureResults of a randomized, controlled, phase II trial. Journal of the American College of Cardiology, 2004, 44, 1181-1186.	2.8	42
70	A Phase 1â€“2 Dose-Escalating Study Evaluating the Safety and Tolerability of Istaroxime and Specific Effects on Electrocardiographic and Hemodynamic Parameters in Patients with Chronic Heart Failure with Reduced Systolic Function. American Journal of Cardiology, 2007, 99, S47-S56.	1.6	41
71	High proportion of patients with end-stage heart failure regardless of aetiology demonstrates anti-cardiac antibody deposition in failing myocardium: humoral activation, a potential contributor of disease progression. European Heart Journal, 2014, 35, 1061-1068.	2.2	41
72	The renin angiotensin system as a risk factor for coronary artery disease. Current Atherosclerosis Reports, 2001, 3, 117-124.	4.8	40

#	Article	IF	Citations
73	Rnd3/RhoE Modulates Hypoxia-Inducible Factor 1Î±/Vascular Endothelial Growth Factor Signaling by Stabilizing Hypoxia-Inducible Factor 1Î± and Regulates Responsive Cardiac Angiogenesis. Hypertension, 2016, 67, 597-605.	2.7	40
74	Atherosclerosis and inflammation. Current Atherosclerosis Reports, 2002, 4, 92-98.	4.8	39
75	A Pilot Safety Trial of Prolonged (48 h) Infusion of the Dual Endothelin-Receptor Antagonist Tezosentan in Patients With Advanced Heart Failure. Chest, 2001, 120, 460-466.	0.8	38
76	Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Current Opinion in Cardiology, 2003, 18, 454-457.	1.8	38
77	A simplified echocardiographic technique for detecting continuous-flow left ventricular assist device malfunction due to pump thrombosis. Journal of Heart and Lung Transplantation, 2014, 33, 575-586.	0.6	38
78	Effects of Spironolactone Treatment in Elderly Women With Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2014, 20, 560-568.	1.7	38
79	What Is the Role of the Inflammation in the Pathogenesis of Heart Failure?. Current Cardiology Reports, 2020, 22, 139.	2.9	36
80	Isolation and chemical identification of lipid derivatives from avocado (Persea americana) pulp with antiplatelet and antithrombotic activities. Food and Function, 2015, 6, 192-202.	4.6	35
81	Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?. Current Opinion in Cardiology, 2008, 23, 254-260.	1.8	34
82	Role of Adaptive Immunity in the Development and Progression of Heart Failure: New Evidence. Archives of Medical Research, 2017, 48, 1-11.	3.3	34
83	Initial Clinical Experience Of Total Cardiac Replacement With Dual Heartmate-II^{Â®}Axial Flow Pumps For Severe Biventricular Heart Failure. Methodist DeBakey Cardiovascular Journal, 2011, 7, 40-44.	1.0	33
84	Imaging for Ventricular Function and Myocardial Recovery on Nonpulsatile Ventricular Assist Devices. Circulation, 2012, 125, 2265-2277.	1.6	33
85	Usefulness of routine surveillance endomyocardial biopsy 6 months after heart transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 845-849.	0.6	33
86	The role of B cells in heart failure and implications for future immunomodulatory treatment strategies. ESC Heart Failure, 2020, 7, 1387-1399.	3.1	33
87	Role of Tumour Necrosis Factor-?? in the Progression of Heart Failure. Drugs, 2000, 59, 745-751.	10.9	32
88	Simvastatin decreases myocardial tumor necrosis factor Î± content in heart transplant recipients. Journal of Heart and Lung Transplantation, 2005, 24, 46-51.	0.6	32
89	Molecular and Cellular Correlates of Cardiac Function in End-Stage DCM. JACC: Cardiovascular Imaging, 2014, 7, 441-452.	5.3	32
90	A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics. European Journal of Heart Failure, 2016, 18, 169-178.	7.1	31

#	Article	IF	Citations
91	Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension. International Journal of Pharmaceutics, 2017, 524, 257-267.	5.2	31
92	Small Interfering RNA Targeting Mitochondrial Calcium Uniporter Improves Cardiomyocyte Cell Viability in Hypoxia/Reoxygenation Injury by Reducing Calcium Overload. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-13.	4.0	31
93	Spinal cord stimulation is safe and feasible in patients with advanced heart failure: early clinical experience. European Journal of Heart Failure, 2014, 16, 788-795.	7.1	30
94	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <scp>VERITAS</scp> study. European Journal of Heart Failure, 2014, 16, 1362-1371.	7.1	28
95	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failureâ€"does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (<scp>VERITAS</scp>). European Journal of Heart Failure, 2017, 19, 739-747.	7.1	28
96	Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against Î² 1 -Adrenergic Receptors. Journal of the American College of Cardiology, 2017, 69, 968-977.	2.8	28
97	The Use of Continuous Milrinone Therapy as Bridge to Transplant Is Safe in Patients With Short Waiting Times. Journal of Cardiac Failure, 2008, 14, 839-843.	1.7	27
98	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. Journal of Cardiac Failure, 2016, 22, 815-822.	1.7	27
99	Impact of pre-operative coronary artery disease on cardiovascular events following lung transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 115-121.	0.6	26
100	The Role of Tumor Necrosis Factor Alpha Blockade in the Treatment of Congestive Heart Failure. Congestive Heart Failure, 2002, 8, 275-279.	2.0	25
101	Immune Modulation in Heart Failure: Past Challenges and Future Hopes. Current Heart Failure Reports, 2011, 8, 28-37.	3.3	25
102	The Role of B-Cells in Heart Failure. Methodist DeBakey Cardiovascular Journal, 2021, 9, 15.	1.0	25
103	Heat shock protein 60 and cardiovascular diseases: An intricate loveâ€hate story. Medicinal Research Reviews, 2021, 41, 29-71.	10.5	25
104	Mast Cell-Derived Cathepsin g: A Possible Role in The Adverse Remodeling of The Failing Human Heart. Journal of Surgical Research, 2007, 140, 199-203.	1.6	24
105	The physiology of cardiovascular disease and innovative liposomal platforms for therapy. International Journal of Nanomedicine, 2013, 8, 629.	6.7	24
106	Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology, 2002, 40, 2165-2173.	2.8	23
107	Effect of the Soluble TNFâ€Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability. Clinical and Translational Science, 2008, 1, 142-145.	3.1	22
108	Cellular Evidence of Reverse Cardiac Remodeling Induced by Cardiac Resynchronization Therapy. Congestive Heart Failure, 2011, 17, 140-146.	2.0	22

#	Article	IF	Citations
109	Combination of angiotensin II and l-NG-nitroarginine methyl ester exacerbates mitochondrial dysfunction and oxidative stress to cause heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H667-H680.	3.2	22
110	Chronic Heart Failure: A Report From the Dartmouth Diastole Discourses. Congestive Heart Failure, 2006, 12, 162-165.	2.0	21
111	Therapeutic plasma exchange a potential strategy for patients with advanced heart failure. Journal of Clinical Apheresis, 2010, 25, 323-330.	1.3	21
112	Resveratrol Prevents Right Ventricle Remodeling and Dysfunction in Monocrotaline-Induced Pulmonary Arterial Hypertension with a Limited Improvement in the Lung Vasculature. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	4.0	21
113	Abnormal Mitochondrial Function During Ischemia Reperfusion Provides Targets For Pharmacological Therapy. Methodist DeBakey Cardiovascular Journal, 2009, 5, 2-7.	1.0	20
114	Systolic blood pressure reduction during the first 24â€‰h in acute heart failure admission: friend or foe?. European Journal of Heart Failure, 2018, 20, 317-322.	7.1	20
115	Cardiac transplantation: the final therapeutic option for the treatment of heart failure. Current Opinion in Cardiology, 2000, 15, 178-182.	1.8	19
116	Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome. European Journal of Heart Failure, 2005, 7, 815-819.	7.1	19
117	Dynamic Expression of the Membrane Attack Complex (MAC) of the Complement System in Failing Human Myocardium. American Journal of Cardiology, 2006, 97, 1626-1629.	1.6	18
118	Recurrent Device Thrombi During Mechanical Circulatory Support With an Axial-flow Pump Is a Treatable Condition and Does Not Preclude Successful Long-term Support. Journal of Heart and Lung Transplantation, 2007, 26, 200-203.	0.6	18
119	Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Current Opinion in Cardiology, 1997, 12, 153-160.	1.8	17
120	Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Current Opinion in Cardiology, 2000, 15, 136-140.	1.8	17
121	Broad Modulation of Tissue Responses (Immune Activation) by Celacade May Favorably Influence Pathologic Processes Associated with Heart Failure Progression. American Journal of Cardiology, 2005, 95, 30-37.	1.6	16
122	Increased Expression of Stem Cell Factor and Its Receptor After Left Ventricular Assist Device Support: A Potential Novel Target for Therapeutic Interventions in Heart Failure. Journal of Heart and Lung Transplantation, 2008, 27, 701-709.	0.6	16
123	The Role of Mast Cells After Solid Organ Transplantation. Transplantation, 2008, 85, 1365-1371.	1.0	16
124	The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. Current Opinion in Cardiology, 1999, 14, 193.	1.8	16
125	The role of inflammation in the pathogenesis of heart failure. Current Cardiology Reports, 2002, 4, 200-205.	2.9	15
126	Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models. International Journal of Molecular Sciences, 2018, 19, 3719.	4.1	15

#	Article	IF	Citations
127	Evolving Concepts Regarding Selection of Patients for Cardiac Transplantation. Chest, 1996, 109, 223-232.	0.8	14
128	Aldosterone antagonism and congestive heart failure: a new look at an old therapy. Current Opinion in Cardiology, 2004, 19, 301-308.	1.8	14
129	The Effect of Etanercept on Cardiac Transplant Recipients: A Study of TNFÎ± Antagonism and Cardiac Allograft Hypertrophy. Transplantation, 2007, 84, 480-483.	1.0	14
130	Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol. BMJ Open, 2019, 9, e022826.	1.9	14
131	A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: The ACCLAIM trial rationale and design. Canadian Journal of Cardiology, 2007, 23, 369-376.	1.7	13
132	Acquired and Hereditary Hypercoagulable States in Patients with Continuous Flow Left Ventricular Assist Devices: Prevalence and Thrombotic Complications. Journal of Cardiac Failure, 2016, 22, 501-511.	1.7	13
133	Use of Stem Cells in Heart Failure Treatment: Where We Stand and Where We Are Going. Methodist DeBakey Cardiovascular Journal, 2021, 9, 195.	1.0	12
134	A Case Series of Reversible Acute Cardiomyopathy Associated with H1N1 Influenza Infection. Methodist DeBakey Cardiovascular Journal, 2021, 8, 42.	1.0	10
135	MANAGING HEART FAILURE WITH IMMUNOMODULATORY AGENTS. Cardiology Clinics, 2001, 19, 617-625.	2.2	9
136	Assessment of Left Ventricular Relaxation by Untwisting Rate Based on Different Algorithms. Journal of the American Society of Echocardiography, 2009, 22, 1040-1046.	2.8	9
137	Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure. Cardio-Oncology, 2018, 4, 3.	1.7	9
138	Molecular, Cellular, and Functional Characterization of Myocardial Regions in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2012, 5, 419-422.	2.6	8
139	Differential Mitochondrial Function in Remodeled Right and Nonremodeled Left Ventricles in Pulmonary Hypertension. Journal of Cardiac Failure, 2016, 22, 73-81.	1.7	8
140	Melding a High-Risk Patient for Continuous Flow Left Ventricular Assist Device into a Low-Risk Patient. ASAIO Journal, 2017, 63, 704-712.	1.6	8
141	B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women: a prospective, multicentre, cross-sectional study. BMJ Open, 2018, 8, e022562.	1.9	8
142	Risk Stratification of Patients With Current Generation Continuous-Flow Left Ventricular Assist Devices Being Bridged to Heart Transplantation. ASAIO Journal, 2018, 64, 196-202.	1.6	7
143	Cobra venom factor, an activator of the complement system, enhances the bowel necrosis induced by platelet-activating factor. Immunopharmacology, 1988, 15, 31-37.	2.0	6
144	Placement of a left ventricular assist device in a patient with dextrocardia. Journal of Heart and Lung Transplantation, 2005, 24, 338-339.	0.6	6

#	Article	IF	Citations
145	Off-pump Exchange of Short-term Percutaneous Ventricular Assist Device (VAD) to Long-term Implantable VAD in Severe Coagulopathy and Multi-organ Failure. Journal of Heart and Lung Transplantation, 2008, 27, 572-574.	0.6	6
146	Standardized extracts from black bean coats (Phaseolus vulgaris L.) prevent adverse cardiac remodeling in a murine model of non-ischemic cardiomyopathy. RSC Advances, 2015, 5, 90858-90865.	3.6	6
147	Novel therapies for heart failure: focus on anti-inflammatory strategies. Congestive Heart Failure, 2006, 12, 153-9; quiz 160-1.	2.0	6
148	New strategies for the management of acute decompensated heart failure. Current Opinion in Cardiology, 2001, 16, 164-173.	1.8	5
149	Role of Endothelial and Mesenchymal Cell Transitions in Heart Failure and Recovery Thereafter. Frontiers in Genetics, 2020, 11, 609262.	2.3	5
150	Powerful immunosuppression mediated by interleukin 2-activated, nonantigen-specific, or H-2-restricted THY-1+ CD8+ cells. Cellular Immunology, 1989, 124, 50-63.	3.0	4
151	Prevalence of inâ€hospital nonsteroidal antiinflammatory drug exposure in patients with a primary diagnosis of heart failure. Cardiovascular Therapeutics, 2017, 35, e12256.	2.5	4
152	Use of a donor heart that had undergone previous cardiac surgery for ASD closure. Journal of Heart and Lung Transplantation, 2002, 21, 294-295.	0.6	3
153	Allograft Coronary Artery Thrombosis: A Case Report Of Early Cardiac Allograft Left Ventricular Myocardial Infarction. Methodist DeBakey Cardiovascular Journal, 2012, 8, 46-48.	1.0	2
154	Pulse assessment is important with blood pressure measurement in individuals with continuous flow left ventricular assist devices. International Journal of Artificial Organs, 2021, 44, 124-129.	1.4	2
155	Cellular, Molecular, Genomic, and Functional Changes That Occur in the Failing Heart in Response to Mechanical Circulatory Support. , 2012, , 258-271.		2
156	Long term development of diastolic dysfunction and heart failure with preserved left ventricular ejection fraction in heart transplant recipients. Scientific Reports, 2022, 12, 3834.	3.3	2
157	The effect of cytokines on cardiac allograft function: tumor necrosis factor alpha a mediator of chronic injury. Heart Failure Reviews, 2001, 6, 137-141.	3.9	1
158	Attenuation of myocardial inflammation by celacadeâ„¢ (Immune modulation therapy) in a murine model of myosin-induced myocarditis. Journal of Cardiac Failure, 2004, 10, S49.	1.7	1
159	The response of the failing heart to chronic mechanical unloading. Current Opinion in Cardiology, 2004, 19, 270-277.	1.8	1
160	Response to Letter by Weidemann et al Regarding Article, â€œGlobal Diastolic Strain Rate for the Assessment of Left Ventricular Relaxation and Filling Pressureâ€. Circulation, 2007, 116, .	1.6	1
161	The use of cardiac CT as a roadmap for resolving coronary stent dislodgement. Archivos De Cardiologia De Mexico, 2018, 88, 318-319.	0.2	1
162	Endothelial Dysfunction-related Neurological Bleeds with Continuous Flow-Left Ventricular Assist Devices Measured by Digital Thermal Monitor. ASAIO Journal, 2021, 67, 561-566.	1.6	1

#	Article	IF	Citations
163	Heart failure, an evolving field: from drugs to novel nonpharmacologic strategies. Current Opinion in Cardiology, 2000, 15, 127.	1.8	0
164	Editorial overview: Cardiac failure. Current Opinion in Cardiology, 2004, 19, 228.	1.8	0
165	Biological and Functional Effects of Chronic Mechanical Support Induced by Left Ventricular Assist Devices on Failing Human Myocardium. , 2005, , 311-328.		0
166	Non-specific immunomodulation in chronic heart failure â€“ Author's reply. Lancet, The, 2008, 371, 2084.	13.7	0
167	Response to Letter Regarding Article, â€œLeft Ventricular Untwisting Rate by Speckle Tracking Echocardiographyâ€• Circulation, 2008, 117, .	1.6	0
168	Heart Failure In Search Of A Cure. Methodist DeBakey Cardiovascular Journal, 2009, 5, 1-1.	1.0	0
169	Heart Failure Research: Translating Basic Science Into Therapies. Methodist DeBakey Cardiovascular Journal, 2009, 5, 38-41.	1.0	0
170	Heart Failure: An Illness at the Juncture of Molecular Medicine and New Technology. Methodist DeBakey Cardiovascular Journal, 2021, 9, 2.	1.0	0
171	Remote versus early corticosteroid wean outcomes in heart transplant recipients in the contemporary era. Clinical Transplantation, 2021, 35, e14382.	1.6	0
172	The Effect of Cytokines on Cardiac Allograft Function: Tumor Necrosis Factor-Î±: A Mediator of Chronic Injury. Developments in Cardiovascular Medicine, 2001, , 77-81.	0.1	0
173	The Cardioprotective Effect of Breg Cells Induced by Methotrexate. FASEB Journal, 2018, 32, 718.6.	0.5	0
174	Abstract 11435: A New Paradigm in Therapy: A Vaccine Against the Progression of Heart Failure. Circulation, 2021, 144, .	1.6	0